Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on […]
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned an average rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year […]
StockNews.com started coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock. A number of other research firms have also commented on SNDX. B. Riley raised their price objective on shares of Syndax Pharmaceuticals from $34.00 to […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $19.14 and last traded at $19.20, with a volume of 34822 shares traded. The stock had previously closed at $19.76. Analyst Upgrades and Downgrades Several research firms have recently weighed in on […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) Director William Meury sold 83,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $20.46, for a total transaction of $1,698,180.00. Following the completion of the sale, the director now owns 48,000 shares in the company, […]